Welcome to our dedicated page for Nuo Therapeutics SEC filings (Ticker: AURX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuo Therapeutics, Inc. filings document a commercial-stage medical-device issuer focused on Aurix, its autologous platelet-rich plasma system for chronic wound management. The company’s regulatory record includes Current Reports on Form 8-K for material events, material agreements, capital-structure disclosures, governance matters, operating and financial results, and security-structure updates.
Proxy and annual-meeting filings describe board elections, auditor ratification, advisory executive-compensation votes, shareholder proposal procedures, and voting results. These disclosures also cover compensation arrangements, board and committee actions, common-stock matters, and public-company governance tied to commercialization of the Aurix System.
Nuo Therapeutics, Inc. reported two governance actions: the board approved salary increases for its top executives and set the date for the 2025 Annual Meeting of Stockholders. Effective October 1, 2025, the salary for Chief Executive and Financial Officer David E. Jorden is $325,000 and the salary for Chief Scientific and Operating Officer Peter A. Clausen is $290,000. The board said the Committee considered an improvement in the company’s business and financial condition in 2025 when approving the increases.
The board fixed the Annual Meeting to be held at the company’s principal executive office on December 16, 2025. Stockholder proposals and director nominations for inclusion in the proxy materials must be received by the company’s Secretary by the close of business on October 20, 2025 and must comply with the company’s By-Laws and SEC rules.